United States Patent 11,154,526 Scope and Claims Analysis for Ethyl Icosapentate (4 g/day) in Atrial Fibrillation on Anticoagulant/Antiplatelet/Thrombolytic Therapy
Executive summary: US 11,154,526 claims a specific triglyceride-lowering method using ethyl icosapentate at about 4 g/day in subjects with atrial fibrillation and/or atrial flutter, who are also on anticoagulant/antiplatelet/thrombolytic therapy and have triglycerides ≥ about 500 mg/dL. Dependent claims narrow to statin co-therapy, defined LDL-C baseline ranges, a high-purity omega-3 composition threshold (≥96 wt.% of omega-3 fatty acids), a capsule dosage structure (about 1 g per 4 capsules), and minimum duration of therapy (≥2 years). The practical infringement perimeter is tightly aligned to a real-world clinical use pattern rather than broad composition or broad dosing, and the patent estate risk profile is driven by (i) whether competing products or labels target the same atrial arrhythmia plus high-triglyceride plus antithrombotic co-therapy population, and (ii) whether generic or label-narrowed strategies can avoid the claim’s defined dose, triglyceride threshold, and therapy duration.
What is claimed in US Drug Patent 11,154,526 (ethyl icosapentate 4 g/day, atrial fibrillation, triglycerides ≥500 mg/dL)?
Claim 1 is a population-and-dose method claim with multiple hard thresholds
Independent claim 1 requires all elements below, in combination:
- Therapeutic context: subject is on anticoagulant/antiplatelet/thrombolytic therapy.
- Index condition: subject has atrial fibrillation and/or atrial flutter.
- Metabolic inclusion criterion: triglyceride levels ≥ about 500 mg/dL.
- Dose and administration: administer about 4 g of ethyl icosapentate per day.
Claim construction implications (practical scope):
- The claim is not a general triglyceride-lowering claim. It is limited to a defined clinical subpopulation (AF/AFL) and a specific concomitant therapy set (antithrombotics).
- The triglyceride threshold of about 500 mg/dL is a gating parameter. Lower TG subjects are outside the claim.
- The daily dose of about 4 g/day is a gating parameter. Approaches that use different dose levels can fall outside the literal wording depending on what “about” covers in claim interpretation.
Dependent claims add label-like refinements
Dependent claims 2 to 6 tighten the clinical and formulation/dosing structure:
- Claim 2: the subject is on statin therapy.
- Claim 3: the subject has baseline LDL-C about 40 to about 100 mg/dL.
- Claim 4: ethyl icosapentate is in a pharmaceutical composition and the ethyl icosapentate comprises at least about 96 wt.% of all omega-3 fatty acids in that composition.
- Claim 5: about 1 g per capsule and 4 capsules to deliver the dosing structure.
- Claim 6: administer the ethyl icosapentate for at least about 2 years.
Together, the dependent claims create multiple “escape hatches” for noninfringing variants. For example, a challenger can avoid infringement if it clearly does not include one or more limiting characteristics (TG threshold, dose, antithrombotic context, AF/AFL, formulation purity profile, LDL-C window, treatment duration, or capsule dosing schema).
How broad is the “about 4 g/day” limitation in claim 1, and what dosing designs increase design-around risk?
Key narrowing lever: exact daily dosing tied to typical commercial regimens
Claim 1 requires “about 4 g … per day,” which is consistent with common high-dose ethyl icosapentate regimens (the dosing is typically represented as 2 g twice daily, but the claim does not require twice-daily split). The phrase “about” introduces interpretive flexibility, but the claim still anchors to a dose level that is likely to be treated as narrow in practice.
Dependent claim 5 further constrains dosing geometry
Claim 5 adds that about 1 g is present in each of 4 capsules. That makes infringement risk much higher for products that dose via 4 × 1 g capsules/day.
Design-around impact:
- A generic or branded competitor using a different unit dosage schedule that does not use the “4 capsules of about 1 g each” dosing pattern can aim to avoid Claim 5 while still potentially implicating Claim 1 if overall daily intake remains “about 4 g/day” in an AF/AFL plus high-TG plus antithrombotic patient.
- A dose regimen that is unambiguously below or above the “about 4 g/day” range could reduce risk against Claim 1, but it may also reduce efficacy and increase payer/label mismatch issues.
What patient inclusion criteria drive infringement risk: atrial fibrillation/flutter plus TG ≥500 mg/dL plus antithrombotic therapy?
Triad requirement: AF/AFL + high triglycerides + antithrombotic therapy
The claim’s novelty perimeter is the convergence of:
- AF/AFL (arrhythmia-driven cohort)
- TG ≥ about 500 mg/dL (hypertriglyceridemia threshold)
- Concomitant antithrombotic class: anticoagulant/antiplatelet/thrombolytic therapy
If any element is absent, the method claim is not met.
Operational ways to reduce risk
- Product use outside AF/AFL patients or outside TG ≥500 mg/dL inclusion criteria reduces direct method exposure.
- A clinical practice guideline that routes AF/AFL high-TG patients to different therapeutic pathways can shift usage away from the patented population-dose combination.
How do dependent claims 2–3 (statin therapy and LDL-C 40–100 mg/dL) narrow the claim estate?
Claim 2: statin co-therapy
Dependent claim 2 requires the subject to be on statin therapy. This is common in cardiovascular populations but not universal.
Risk note for competitors:
Even if a competitor targets AF/AFL and high TG, if their intended population excludes statin users (or if they label/narrow to statin-naïve or low LDL populations), they may reduce coverage under Claim 2.
Claim 3: baseline LDL-C window
Claim 3 requires baseline LDL-C about 40 to about 100 mg/dL.
Practical consequences:
- For clinicians treating AF/AFL patients with very low LDL (e.g., aggressive PCSK9/statin regimens) or with LDL outside this window, Claim 3 may not apply.
- It also creates a data-anchored infringement gate. A challenger can argue that the prescribed population does not meet that LDL-C range.
What formulation limitations exist in claim 4 (≥96 wt.% omega-3 fatty acids purity), and how can generics avoid it?
Claim 4 is a compositional purity requirement tied to omega-3 fatty acid distribution
Claim 4 requires that in the pharmaceutical composition:
- ethyl icosapentate comprises at least about 96 wt.% of all omega-3 fatty acids in the composition.
This is not a general “contains omega-3” limitation. It is a purity/distribution ratio limitation that is likely to map to product specs tied to the predominance of EPA-containing material.
Design-around routes
- Use of an omega-3 mixture that reduces the relative proportion of ethyl icosapentate within “all omega-3 fatty acids” below the 96 wt.% threshold could avoid Claim 4.
- A label strategy that uses a different omega-3 active profile could also reduce formulation coverage, but it may diverge from the intended clinical effect and from the product’s established regulatory classification.
Does claim 5 effectively lock in a 1 g capsule and 4-capsule daily regimen?
Claim 5 is a dosage-form and unit-structure limitation
Claim 5 requires:
- about 1 g pharmaceutical composition per capsule
- 4 capsules for the relevant daily dosing structure
This is a strong limiter against competitors whose unit-dose is not structured as “1 g capsules x4 per day,” even if the overall daily amount is similar.
Infringement mapping:
- A competitor with 0.5 g capsules requiring 8 capsules/day may attempt to avoid this specific limitation.
- However, Claim 1 could still capture them if the method still administers “about 4 g/day” to a covered patient population.
What does claim 6 require about duration (≥2 years), and how does that affect litigation and label strategy?
Claim 6 adds a minimum course length
Claim 6 requires the ethyl icosapentate is administered for at least about 2 years.
Claim coverage consequences:
- A prescribing approach using shorter treatment durations can evade Claim 6.
- A trial or label limited to a shorter horizon could reduce the chance of satisfying this limitation in practice.
Litigation relevance:
- If parties are challenging enforcement, duration can become a record-based factual question (prescription duration, adherence, persistence).
- Design-around strategies can target treatment duration while preserving dose and patient inclusion, though that may impact clinical objectives.
How does this patent’s method focus compare with composition-only or broad omega-3 patents?
Method claim scope vs. formulation claim scope
US 11,154,526 is primarily a method-of-use style patent anchored to:
- patient condition and concurrent therapy
- TG inclusion threshold
- dose
- with dependent claims that add formulation purity and unit structure
Compared with broader patents that cover:
- general ethyl icosapentate compositions,
- general hypertriglyceridemia treatment,
- general use in cardiovascular patients,
this patent is narrower because it specifies a subpopulation + concomitant antithrombotic therapy + exact dose. That narrows infringement to real-world prescribing patterns that match the claim.
Comparison to typical omega-3 IP patterns
In omega-3 portfolios, composition and process patents can be easier for generics to challenge on “non-use” and “label carve-out,” while method patents rely heavily on indication-specific prescribing behavior. This patent’s inclusion of AF/AFL and antithrombotic therapy intensifies the need for a factual prescribing profile, not just the existence of a drug containing ethyl icosapentate.
Patent landscape for competitors: what types of filings and strategies are most likely to intersect this claim?
1) Generic ethyl icosapentate approvals with an aligned label
If a generic’s label and intended use align with:
- AF/AFL patient subsets,
- TG ≥500 mg/dL,
- and dose at/near 4 g/day,
then method infringement risk rises, especially where the therapy duration and formulation purity match dependent claims.
2) Label narrowing to avoid dependent claim conditions
If a label or prescribing guidance intentionally avoids statin co-therapy as a required population characteristic (Claim 2) or targets LDL-C outside 40–100 mg/dL (Claim 3), then coverage against dependent claims can be reduced, though Claim 1 may still remain.
3) Unit dosage changes to avoid Claim 5
A generic with different capsule strength and count can avoid literal correspondence to Claim 5, but cannot avoid Claim 1 if daily dose and patient conditions match.
4) Therapy duration strategies to avoid Claim 6
A shorter-course label or use that targets improvement over less than two years can avoid Claim 6, but Claim 1 can still apply if all other limitations are satisfied.
What Orange Book status is implied, and what is the likely “carve-out” leverage for generics?
No Orange Book listing or expiration data is provided in the prompt, and the patent number alone is insufficient to reliably determine:
- which FDA-listed drug product(s) are tied to US 11,154,526,
- whether it is listed for specific NDA/BLA references, and
- the patent expiration date or any pediatric exclusivity extensions.
Under the stated constraints, no status claims are included.
Timeline analysis: when could method coverage realistically be avoided based on claim design-around rather than patent expiration?
Using claim gates as “non-infringing routes”
Instead of waiting for expiration, parties can reduce coverage by steering usage away from one or more required elements:
- shift to patients without AF/AFL
- treat TG below the ≥500 mg/dL threshold
- use a different ethyl icosapentate dose not “about 4 g/day”
- avoid statin co-therapy as a targeting criterion (Claim 2)
- use patient populations with LDL-C outside 40–100 mg/dL (Claim 3)
- ensure formulation does not meet ≥96 wt.% omega-3 distribution (Claim 4)
- alter unit-dose to not match 1 g capsules and 4 capsules/day (Claim 5)
- use therapy courses shorter than about 2 years (Claim 6)
These are the key “engineering levers” implied by the claim language, and they map to label language, clinical inclusion criteria, and product presentation.
Key Takeaways
- US 11,154,526 is a tightly bounded method claim: it requires AF/AFL, anticoagulant/antiplatelet/thrombolytic therapy, TG ≥ about 500 mg/dL, and ethyl icosapentate at about 4 g/day.
- Dependent claims add further gates that materially change infringement scope: statin use, LDL-C 40–100 mg/dL, ≥96 wt.% omega-3 purity metric, 1 g capsule × 4/day structure, and ≥2 years duration.
- Non-infringing strategies are feasible only when they break at least one required limitation. Dose and patient selection are primary levers for Claim 1. Formulation purity, capsule structure, and duration are secondary levers for dependent claims.
- Litigation exposure is fact-dependent on prescribing behavior and patient lab values, not only on drug identity.
FAQs
1) If a patient has atrial fibrillation but triglycerides are 450 mg/dL, does US 11,154,526 apply?
No. Claim 1 requires triglycerides at least about 500 mg/dL.
2) Can a competitor avoid claim coverage by using a different omega-3 product with lower ethyl icosapentate omega-3 purity?
It can reduce risk of satisfying Claim 4 if the formulation does not meet the ≥96 wt.% of omega-3 fatty acids requirement, but Claim 1 can still apply if the other limitations are met.
3) Does using ethyl icosapentate for 18 months avoid the patent?
It can avoid satisfying Claim 6 because it requires at least about 2 years, but it does not avoid Claim 1 if the other Claim 1 limitations are met.
4) If a generic uses 2 g twice daily but not “1 g capsules ×4,” is it still captured?
It may still meet Claim 1 if the daily administered amount is “about 4 g/day” and the patient meets the inclusion criteria. Avoidance of Claim 5 depends on unit-dose and capsule-structure compliance.
5) What is the most sensitive element for design-around?
The most sensitive element is usually the combination of AF/AFL + antithrombotic therapy + triglycerides ≥500 mg/dL + about 4 g/day because it is built into Claim 1.
References (APA)
- User-provided claim text for US Drug Patent 11,154,526.
